The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and Eli Lilly (LLY) have witnessed tremendous success, which has played a key role in the industry’s outperformance.  Large drugmakers have several robust revenue streams and are mostly profitable companies, which makes them safe havens for investments. Innovation is key to the growth of the industry. Innovation ...